News

DCCR Leads to Continuous Reductions in Hyperphagia, Other Symptoms

Daily treatment with diazoxide choline controlled release (DCCR) leads to sustained reductions in excessive appetite and other symptoms of Prader-Willi syndrome (PWS), according to updated findings from a Phase 3 trial. “The results from this program continue to demonstrate DCCR’s beneficial impact on hyperphagia [excessive appetite], the…

Lallemand, PWSA Become Running Partners to Support Fundraiser

Lallemand Health Solutions has partnered with the Prader-Willi Syndrome Association (PWSA) to support Running for Research, an initiative to raise funds for PWS research at the University of Florida (UF). Running for Research has set a fundraising goal of at least $40,000, and will take place…

Inversago Raises $35M to Develop Therapies for PWS, Other Disorders

Inversago Pharma has obtained $35 million in financing to advance the development of therapies for disorders such as Prader-Willi syndrome (PWS). The investment will support studies of INV-101, the company’s lead compound, and other selected compounds for the treatment of metabolic and fibrotic (scarring) disorders. INV-101 is an…